PHARMAN
ActiveSummary
PHARMAN has been active since 1998 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €340,968 and a net result of €49,709. Equity has been growing by about 22% per year since 2019. Its solvency ranks better than 50% of 9,662 sector peers (NACE 82, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).
Overview
Overview
Official details
Source: KBO- Status
- Active since 22-10-1998 Normal situation
- Activity
- Office administrative and support services NACE 82100and 4 others
- Establishment unit
- 2.089.115.526 2900 Schoten, since 15-11-2001
- Financial year end
- 30 September
- Peppol
- Reachable since 30-12-2025
Financial position
- Bankruptcy probabilitywithin 12 months
- 0.2%
Annual accounts to 30-09-2025
- Gross margin
- €97,176
- ▼ 37.7%
- Turnover
- ≈ €200,000
- estimated
- Profit
- €49,709
- ▼ 57.1%
- Equity
- €340,968
- ▲ 17.1%
- Total assets
- €682,751
- ▲ 6.0%
Score breakdownraises risk1 of the last 3 accounts lateLiquidity: current ratio 5.29, cash €11,215, halvedProfit of €49,709 (financial year 2025)lowers riskSize: total assets €682,751Show the evidence
Checked score
Score 2025
89
/ 100
Excellent
Probability in this band: under 0.55%
Financially stronger than 52% of micro companies in office administrative support (NACE 82)
Financial strength · tick: 2024
Strong
Solvency
75+5
equity 49.9% of total assets
Liquidity
52-11
short-term debt 8.2% · cash 1.6%
Profitability
78-13
return on assets 7.3%
Bankruptcy probability within 12 months
0.2%
Very low
0%0.5%1.5%4%10%≥ 25%
About 2 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.3%
01-2025: 0.2%▼ -0.1 percentage points vs 12-2024
02-2025: 0.3%▲ +0.1 percentage points vs 01-2025
03-2025: 0.3%● unchanged vs 02-2025
04-2025: 0.3%● unchanged vs 03-2025
05-2025: 0.5%▲ +0.2 percentage points vs 04-2025highest value
06-2025: 0.1%▼ -0.4 percentage points vs 05-2025
07-2025: 0.1%● unchanged vs 06-2025
08-2025: 0.1%● unchanged vs 07-2025
09-2025: 0.1%● unchanged vs 08-2025
10-2025: 0.1%● unchanged vs 09-2025
11-2025: 0.1%● unchanged vs 10-2025
12-2025: 0.1%● unchanged vs 11-2025
01-2026: 0.1%● unchanged vs 12-2025lowest value
02-2026: 0.1%● unchanged vs 01-2026
03-2026: 0.1%● unchanged vs 02-2026
04-2026: 0.2%▲ +0.1 percentage points vs 03-2026
05-2026: 0.3%▲ +0.1 percentage points vs 04-2026
06-2026: 0.2%▼ -0.1 percentage points vs 05-2026
07-2026: 0.2%● unchanged vs 06-2026
08-2026: 0.2%● unchanged vs 07-2026
09-2026: 0.2%● unchanged vs 08-2026
10-2026: 0.2%● unchanged vs 09-2026
11-2026: 0.2%● unchanged vs 10-2026
Credit of up to €30,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 5.29 (5.51 in 2024), above the usual 1.5. Short-term debt is 8.2% and cash 1.6% of total assets. However, 50.1% of the assets are financed with debt and provisions.
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 82, micro). It does better than 51% of them on solvency, 44% on liquidity, 49% on profitability and 63% on growth.
The bankruptcy probability was computed on 02-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 30-09-2025 was due by 30-04-2026 and was filed on 30-04-2026, 0 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
on the day
2024
6 days late
2023
45 days late
2022
4 days early
2021
51 days early
2020
12 days late
2019
29 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 5 days after the deadline. In the sector (NACE 82), the median for financial year 2024 was 7 days before the deadline, and 35% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The financial year that closed on 30-09-2026 is due by 30-04-2027. Nothing is late today. The company usually files around 30 April (4 of the last 5 accounts filed within 46 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
30-09-2026 year end03-11-2026 today30-04-2027 deadline
Financials
Financials · financial year 2025, micro format
Annual accounts 2025 filed on 30-04-2026 PDF all 26 filings
Turnover
≈ €200,000
Estimated: probably between €160,000 and €270,000
Total assets
€682,751▲ 6.0%
2024 · €644,096
Net result
€49,709▼ 57.1%
2024 · €115,860
Working capital
€239,627▲ 21.1%
2024 · €197,808
Multi-year overview
2019 to 2025, 7 financial yearsOperating result
€78,450
▼ 42.3%
2025
20192025
Net result
€49,709
▼ 57.1%
2025
highest quarter of the sector
20192025
Equity
€340,968
▲ 17.1%
2025
highest quarter of the sector
20192025
Total assets
€682,751
▲ 6.0%
2025
highest quarter of the sector
20192025
Debt
€341,783
▼ 3.1%
2025
20192025
Working capital
€239,627
▲ 21.1%
2025
highest quarter of the sector
20192025
Solvency
49.9%
▲ 4.7pp
2025
middle half of the sector
20192025
Current ratio
5.29
▼ 0.22
2025
highest quarter of the sector
20192025
Return on assets (ROA)
7.3%
▼ 10.7pp
2025
middle half of the sector
20192025
Staff (FTE)
no figure
2025
20192025
Every figure per financial year
Every figure with its change against the financial year before
favourable
unfavourable
Line2019202020212022202320242025
Operating result-€65,840-€19,419€82,992▲ 327%€38,182▼ 54.0%€34,254▼ 10.3%€135,916▲ 297%€78,450▼ 42.3%
Net result-€46,368--€14,341below the sector's middle half▲ 69.1%€73,033above the sector's middle half€32,000within the sector's middle half▼ 56.2%€24,451within the sector's middle half▼ 23.6%€115,860above the sector's middle half▲ 374%€49,709above the sector's middle half▼ 57.1%
Equity€108,068-€93,727within the sector's middle half▼ 13.3%€166,760above the sector's middle half▲ 77.9%€198,760above the sector's middle half▲ 19.2%€223,211above the sector's middle half▲ 12.3%€291,259above the sector's middle half▲ 30.5%€340,968above the sector's middle half▲ 17.1%
Total assets€159,909-€128,456within the sector's middle half▼ 19.7%€188,802within the sector's middle half▲ 47.0%€589,066above the sector's middle half▲ 212%€583,454above the sector's middle half▼ 1.0%€644,096above the sector's middle half▲ 10.4%€682,751above the sector's middle half▲ 6.0%
Debt€51,841-€34,729▼ 33.0%€22,042▼ 36.5%€390,306▲ 18×€360,243▼ 7.7%€352,837▼ 2.1%€341,783▼ 3.1%
Working capital€101,675-€93,727above the sector's middle half▼ 7.8%€154,310above the sector's middle half▲ 64.6%€146,010above the sector's middle half▼ 5.4%€161,775above the sector's middle half▲ 10.8%€197,808above the sector's middle half▲ 22.3%€239,627above the sector's middle half▲ 21.1%
Solvency67.6%-73.0%above the sector's middle half▲ 5.4pp88.3%above the sector's middle half▲ 15.4pp33.7%within the sector's middle half▼ 54.6pp38.3%within the sector's middle half▲ 4.5pp45.2%within the sector's middle half▲ 7.0pp49.9%within the sector's middle half▲ 4.7pp
Current ratio2.96-3.70within the sector's middle half▲ 0.748.00above the sector's middle half▲ 4.304.95above the sector's middle half▼ 3.056.61above the sector's middle half▲ 1.665.51above the sector's middle half▼ 1.115.29above the sector's middle half▼ 0.22
Return on assets (ROA)-29.0%--11.2%below the sector's middle half▲ 17.8pp38.7%above the sector's middle half▲ 49.8pp5.4%within the sector's middle half▼ 33.2pp4.2%within the sector's middle half▼ 1.2pp18.0%within the sector's middle half▲ 13.8pp7.3%within the sector's middle half▼ 10.7pp
Staff (FTE)0.3-
above
within
below
The sector band is the middle half of the companies in Office administrative, office support and other business support activities (NACE 82). A quarter of them sit below it, a quarter above. Each year counts only accounts in the same format, and only where there are at least 30.
The operating result for 2025 is 42% lower than in 2024.
Turnover and EBIT margin are not published. The abbreviated or micro format does not require them. The turnover shown is an estimate from the gross margin.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €682,751
Fixed assets
€387,253 ▼ 3.8%
Current assets
€295,498 ▲ 22.3%
Equity and liabilities €682,751
Equity
€340,968 ▲ 17.1%
Debt
€341,783 ▼ 3.1%
Debt's share of the balance-sheet total falls from 54.8% to 50.1%. Equity is higher and debt is lower.
Key figures and ratios
EBITDA
€93,583▼
2024 · €149,643
Cash flow
€64,843▼
2024 · €129,587
Debt to equity
1.00▼
2024 · 1.21
ROE
14.6%▼
2024 · 39.8%
Interest coverage
11.76▼
2024 · 17.61
Debt ≤ 1 year
€55,871▲
2024 · €43,902
Debt > 1 year
€285,912▼
2024 · €308,935
Income taxes
€24,136▲
2024 · €11,586
Green means a favourable move, even when the figure itself falls, as with debt or debt to equity.
Securities and guarantees
| Item | 30-09-2022 | 30-09-2023 | 30-09-2024 | 30-09-2025 |
|---|---|---|---|---|
| Mortgages, amount registered | €110,000 | €110,000 | €110,000 | - |
| Mortgage mandates | €308,000 | €308,000 | €308,000 | - |
| Carrying value of the mortgaged assets | €396,557 | €386,255 | €402,386 | - |
| Pledge on the business | €330,000 | €330,000 | €330,000 | - |
Source: notes to the 2022 to 2025 annual accounts (statement of debts and off-balance-sheet rights and commitments)
Investments
| Item | 30-09-2022 | 30-09-2023 | 30-09-2024 | 30-09-2025 |
|---|---|---|---|---|
| Tangible fixed assets | €400,000 | - | €23,267 | - |
| Depreciation and write-downs of the year | €6,373 | €13,232 | €13,726 | €15,134 |
Source: notes to the 2022 to 2025 annual accounts (statement of fixed assets)
Subsidies and aid
Flemish government
2022 to 2023 · 2 entries · €2,009 awarded · €2,009 paid| Year | Entries | Awarded | Paid |
|---|---|---|---|
| 2023 | 1 | €0 | €2,009 |
| 2022 | 1 | €2,009 | €0 |
Annual accounts
| Line | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|
| Remuneration, social security and pensions62 | - | - | - | €2,071 | - | - | - | - |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €6,393 | €6,392 | €2,197 | €6,373 | €13,232 | €13,726 | €15,134 | ▲ 10.3% |
| Other operating charges640/8 | - | - | - | €2,037 | €3,228 | €6,432 | €3,593 | ▼ 44.1% |
| Gross operating margin9900 | -€39,308 | €26,500 | €86,639 | €48,663 | €50,713 | €156,075 | €97,176 | ▼ 37.7% |
| Operating profit (loss)9901 | -€65,840 | €19,419 | €82,992 | €38,182 | €34,254 | €135,916 | €78,450 | ▼ 42.3% |
| Financial income75/76B | - | - | - | €10 | €1,604 | €28 | €3,352 | ▲ 120× |
| Recurring financial income75 | €26,112 | - | - | €10 | €1,604 | €28 | €3,352 | ▲ 120× |
| Financial charges65/66B | - | - | - | €2,904 | €8,962 | €8,498 | €7,957 | ▼ 6.4% |
| Recurring financial charges65 | €6,640 | €33,759 | €76 | €2,904 | €8,962 | €8,498 | €7,957 | ▼ 6.4% |
| Profit (loss) for the period before taxes9903 | -€46,368 | -€14,341 | €82,917 | €35,287 | €26,896 | €127,446 | €73,845 | ▼ 42.1% |
| Income taxes67/77 | - | - | €9,884 | €3,287 | €2,445 | €11,586 | €24,136 | ▲ 108% |
| Profit (loss) for the period9904 | -€46,368 | -€14,341 | €73,033 | €32,000 | €24,451 | €115,860 | €49,709 | ▼ 57.1% |
| Profit (loss) for the period to be appropriated9905 | -€46,368 | -€14,341 | €85,936 | €32,000 | €24,451 | €115,860 | €49,709 | ▼ 57.1% |
| Line | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Total assets20/58 | €159,909 | €128,456 | €188,802 | €589,066 | €583,454 | €644,096 | €682,751 | ▲ 6.0% |
| Fixed assets21/28 | €6,392 | - | €12,450 | €406,078 | €392,846 | €402,386 | €387,253 | ▼ 3.8% |
| Tangible fixed assets22/27 | €6,392 | - | €12,450 | €406,078 | €392,846 | €402,386 | €387,253 | ▼ 3.8% |
| Land and buildings22 | - | - | - | €396,557 | €386,255 | - | - | - |
| Other tangible fixed assets26 | - | - | - | €9,521 | €6,591 | €402,386 | €387,253 | ▼ 3.8% |
| Current assets29/58 | €153,517 | €128,456 | €176,352 | €182,988 | €190,608 | €241,710 | €295,498 | ▲ 22.3% |
| Amounts receivable within one year40/41 | €99,961 | €82,881 | €115,859 | €169,099 | €178,394 | €175,548 | €209,251 | ▲ 19.2% |
| Trade receivables40 | - | - | - | €127,987 | €124,606 | €67,995 | €76,928 | ▲ 13.1% |
| Other amounts receivable41 | - | - | - | €41,112 | €53,787 | €107,553 | €132,323 | ▲ 23.0% |
| Current investments50/53 | - | - | - | - | - | - | €70,898 | - |
| Cash at bank and in hand54/58 | €53,556 | €45,575 | €60,493 | €13,889 | €10,621 | €66,161 | €11,215 | ▼ 83.0% |
| Deferred charges and accrued income490/1 | - | - | - | - | €1,594 | - | €4,134 | - |
| Equity and liabilities | ||||||||
| Total equity and liabilities10/49 | €159,909 | €128,456 | €188,802 | €589,066 | €583,454 | €644,096 | €682,751 | ▲ 6.0% |
| Equity10/15 | €108,068 | €93,727 | €166,760 | €198,760 | €223,211 | €291,259 | €340,968 | ▲ 17.1% |
| Contributions10/11 | €12,400 | - | - | €12,400 | €12,400 | €12,400 | €12,400 | = |
| Reserves13 | €60,716 | €60,716 | €133,749 | €165,749 | €190,200 | €258,247 | €328,568 | ▲ 27.2% |
| Distributable reserves133 | - | - | - | €165,749 | €190,200 | €258,247 | €328,568 | ▲ 27.2% |
| Profit (loss) carried forward14 | €34,952 | €20,611 | €20,611 | €20,611 | €20,611 | €20,611 | - | - |
| Amounts payable17/49 | €51,841 | €34,729 | €22,042 | €390,306 | €360,243 | €352,837 | €341,783 | ▼ 3.1% |
| Amounts payable after more than one year17 | - | - | - | €353,327 | €331,410 | €308,935 | €285,912 | ▼ 7.5% |
| Financial debts170/4 | - | - | - | €353,327 | €331,410 | €308,935 | €285,912 | ▼ 7.5% |
| Amounts payable within one year42/48 | €51,841 | €34,729 | €22,042 | €36,978 | €28,833 | €43,902 | €55,871 | ▲ 27.3% |
| Current portion of amounts payable after more than one year42 | - | - | - | €21,418 | €21,917 | €22,475 | €23,023 | ▲ 2.4% |
| Trade debts44 | - | €546 | €1,858 | €5,158 | €2,057 | €4,392 | €1,747 | ▼ 60.2% |
| Suppliers440/4 | - | - | - | €5,158 | €2,057 | €4,392 | €1,747 | ▼ 60.2% |
| Taxes, remuneration and social security45 | - | - | - | €10,403 | €4,859 | €14,645 | €30,311 | ▲ 107% |
| Taxes450/3 | - | - | - | €10,403 | €4,859 | €14,645 | €23,145 | ▲ 58.0% |
| Remuneration and social security454/9 | - | - | - | - | - | - | €7,167 | - |
| Other amounts payable47/48 | - | - | - | - | - | €2,391 | €790 | ▼ 67.0% |
| Line | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | -€46,368 | -€14,341 | €73,033 | €32,000 | €24,451 | €115,860 | €49,709 | ▼ 57.1% |
| + Depreciation and write-downs630 | €6,393 | €6,392 | €2,197 | €6,373 | €13,232 | €13,726 | €15,134 | ▲ 10.3% |
| Operating cash flow (approximation) | -€39,976 | -€7,948 | €75,230 | €38,373 | €37,682 | €129,587 | €64,843 | ▼ 50.0% |
| Investment in fixed assets (approximation) | - | - | - | -€400,000 | €0 | -€23,267 | €0 | - |
| Change in cash | - | -€7,981 | €14,917 | -€46,603 | -€3,268 | €55,540 | -€54,946 | - |
A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.
Historical observation
In July 2024, 20,136 companies had the same profile as PHARMAN has now. Two years later, 95.0% were still going and 0.2% had gone bankrupt.
- Small
- 20 years or older
- solvency 30% or more
- a profit of 5% of the balance sheet or more
95.0%
was still going
4.7%
stopped otherwise
0.2%
went bankrupt
That fits the bankruptcy probability of PHARMAN itself: 0.2% within 12 months.
Test of the method
The method was tested on the 497,446 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 20,136 companies, not a prediction for PHARMAN. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Latest 10 of 26 filings with the National Bank
| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 30-09-2025 | micro format | 30-04-2026 | 2026-00104603 | |
| 30-09-2024 | micro format | 06-05-2025 | 2025-00090951 | |
| 30-09-2023 | micro format | 14-06-2024 | 2024-00133101 | |
| 30-09-2022 | micro format | 26-04-2023 | 2023-00067681 | |
| 30-09-2021 | micro format | 10-03-2022 | 2022-07400518 | |
| 30-09-2020 | micro format | 12-05-2021 | 2021-14000311 | |
| 30-09-2019 | abbreviated format | 29-05-2020 | 2020-13600287 | |
| 30-09-2018 | abbreviated format | 17-05-2019 | 2019-13700111 | |
| 30-09-2017 | abbreviated format | 28-05-2018 | 2018-14700207 | |
| 30-09-2016 | abbreviated format | 28-04-2017 | 2017-10800359 |
Board & ownership
Directors
Directors
1 director, last change in 2024
Goetschalckx Marleen
Current
Director (not named in the articles) · appointed in the act of 22-01-2024 · term without a fixed end · listed in the 2022 annual accounts, filed on 26-04-2023
Owners and capital
Owners
Network & group
PHARMAN shares no director with another company.
Companies at the same address
2 other companiesConnections & network
1 current directorThe network starts from the directors of PHARMAN. Every other company they run is a node.
This company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, zoom with the mouse wheel.
Timeline
Acts, filings and financial milestones
Deadline for the 2026 accounts:
2026
30-04
micro format · on the deadline day
2025
06-05
micro format · 6 days late
2024
30-09
Financial
Highest result from 2019 to 2025net €115,860 ▲374%
The operating result of €135,916 and the net result of €115,860 are both a record.
14-06
micro format · 45 days late
22-01
Gazette deed
Appointment: Goetschalckx Marleen (director)Amendment of the articles · Capital conversion · Registered office clause8 points ▸
Gazette deed
Appointment: Goetschalckx Marleen (director)
Amendment of the articles · Capital conversion · Registered office clause8 points ▸
- General meeting, “unanimiteit van stemmen, buitengewone algemene vergadering” (deed in Dutch)
- Amendment of the articles, mentioned 2 times in the deed
- Capital conversion, “kapitaal aan Wetboek van vennootschappen en verenigingen, aanpassing” (deed in Dutch)
- Other provision, “beschikbaar maken statutair onbeschikbaar eigen vermogen, beschikbaar maken” (deed in Dutch)
- Other provision, “vermindering eigen vermogensrekening niet-volgestorte inbrengen - vrijstelling volstortingsplicht, vermindering+vrijstelling” (deed in Dutch)
- Registered office clause, “Ganzendreef 1,2900 Schoten”, 8 (deed in Dutch)
- Director appointment, Goetschalckx Marleen (director (not named in the articles))
- Power of attorney
2023
30-09
Financial
Equity above €200,000equity €223,211 ▲12.3%
After 3 profitable years in a row, equity reaches €223,211.
26-04
micro format · 4 days before the deadline
2022
10-03
micro format · 51 days before the deadline
2021
30-09
Financial
Back to profitnet €73,033
The net result is €73,033, after 2 loss-making years.
30-09
Financial
Liquidity more than doubledcurrent ratio 8.00
The current ratio rises from 3.70 to 8.00. Short-term debt falls from €34,729 to €22,042.
30-09
Financial
Equity above €150,000equity €166,760 ▲77.9%
Equity rises from €93,727 to €166,760.
12-05
micro format · 12 days late
Show earlier events
2020
29-05
abbreviated format · 29 days late
2019
17-05
abbreviated format · 17 days late
2018
28-05
abbreviated format · 28 days late
2017
28-04
abbreviated format · 2 days before the deadline
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
Sources:Publications in the Belgian Official GazetteFilings with the National Bank
History
Company details
Register details
Identity
KBO recordName
PHARMAN in Dutch
Enterprise number
0464.428.377
Legal form
Private limited company
Status
Active, normale toestand
Founded
22-10-1998
Entity type
Legal entity
Registered office and establishments
Registered office
Ganzendreef 1, 2900 Schoten, Belgium
Establishment unit
PHARMAN, Ganzendreef 1, 2900 Schoten since 15-11-2001 · unit number 2.089.115.52662100 Computer programming
Activities
NACEBEL 202582100
Office administrative and support services main activity
62200
Computer consultancy and computer facilities management
64210
Activities of holding companies
68110
Buying and selling of own real estate
68201
Renting and operating of own or leased residential real estate, excluding social housing
Codes under NACEBEL 2008
82190
Office administrative, office support and other business support activities main activity
62020
IT consultancy
64200
Holdings
68100
Real estate activities
68201
Real estate activities
Codes under NACEBEL 2003
74851
main activity
70120
70201
72100
74151
Invoicing and payment
VAT number
BE 0464.428.377
Financial year and general meeting
Accounts at the NBBFinancial year end
30-09
Sites & property
Location
Buildings and parcels at the address
Ground area
4,827 m²
Building footprint
250 m²
Building volume
1,751 m³
| Cadastral parcel | Region | Area | Buildings | Height / floors |
|---|---|---|---|---|
| 11040A0111/00S010 | Flanders | 4,827 m² | 1 · 250 m² | 11.1 m · 2 |